Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Demcizumab [USAN:INN]
RN: 1243262-17-0


  • Targets DLL4.

    NCI: A humanized monoclonal antibody directed against the N-terminal epitope of Notch ligand DLL4 (delta-like 4) with potential antineoplastic activity. Demcizumab binds to the membrane-binding portion of DLL4 and prevents its interaction with Notch-1 and Notch-4 receptors, thereby inhibiting Notch-mediated signaling and gene transcription, which may impede tumor angiogenesis. Activation of Notch receptors by DLL4 stimulates proteolytic cleavage of the Notch intracellular domain (NICD); after cleavage, NICD is translocated into the nucleus and mediates the transcriptional regulation of a variety of genes involved in vascular development. The expression of DLL4 is highly restricted to the vascular endothelium. (NCI Thesaurus)
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Demcizumab [USAN:INN]


  • Demcizumab
  • OMP 21M18
  • OMP-21M18
  • UNII-SF168W7FW0

Registry Numbers

CAS Registry Number

  • 1243262-17-0


  • SF168W7FW0

System Generated Number

  • 1243262170